// App-Quantinova.ai

626 : Trial in progress: an intravenously administered second-generation STING agonist, BI 1703880 with a novel lead-in design in combination with ezabenlimab

Researchers

Presenter

  • Kevin Harrington

Principal Investigators

  • Elizabeth Dowling

  • Robert Latek

  • Michael Schmohl

  • Patricia LoRusso

Medical Centers

  • Royal Marsden NHS Foundation Trust, London, UK

  • Yale Cancer Center, New Haven, CT

  • Boehringer Ingelheim International GmbH, Biberach, Germany

Locations

  • United Kingdom

  • United States

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Autoimmune (AI)

Disease

  • Cytokine release syndrome

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Interferon

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

  • Open Label

  • Dose Escalation

  • First-In-Human

Phase

  • I

Study Id's

  • N/A

Sponsors

  • Boehringer Ingelheim International GmbH

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved